ASCO: Controversies in Phase I Clinical Trials

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials.

Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials: how physicians should present these clinical trials to patients-phase I trials typically have very low response rates (5% to 10%)-and explain their purpose without exaggerating the likely results.

Recent Videos
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
It can cause thrombocytopenia and diarrhea, which are generally manageable and not too big a deal.
Related Content
Iberdomide Combo Leads to Deepening Responses in Transplant-Ineligible NDMM

Iberdomide Combo Leads to Deepening Responses in Transplant-Ineligible NDMM

Ashling Wahner
September 19th 2025
Article

Iberdomide with daratumumab and dexamethasone led to an ORR of 93.1%, with stringent CRs in 30.1%, in those with newly diagnosed multiple myeloma.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The long-term safety profile of equecabtagene autoleucel was manageable, with no new safety signals identified in those with multiple myeloma.

Eque-Cel Displays Favorable Long-Term Survival in R/R Multiple Myeloma

Roman Fabbricatore
September 19th 2025
Article

The long-term safety profile of equecabtagene autoleucel was manageable, with no new safety signals identified in those with multiple myeloma.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

With a median follow-up of 6 months from diagnosis and 15 months from diagnosis, 0% of the 17 evaluable patients reported any progression events.

BPd Maintenance Safe, Yields Responses in High-Risk Multiple Myeloma

Tim Cortese
September 19th 2025
Article

Patients with high-risk multiple myeloma who received BPd maintenance therapy reported no events of progression in the phase 2 trial.

ISB 2001 Yields Durable Responses, Manageable Safety in R/R Multiple Myeloma

ISB 2001 Yields Durable Responses, Manageable Safety in R/R Multiple Myeloma

Ashling Wahner
September 18th 2025
Article

Treatment with ISB 2001 led to an overall response rate of 74% across dose levels 1 to 9 in patients with relapsed/refractory multiple myeloma.